Featured Article

Queen Mary University of London researchers evaluated whether genetic variants linked to type 2 diabetes in Europeans are also relevant in British Pakistani and Bangladeshi people.

Precision Oncology Today

Magazine

Circulating Tumor DNA is Increasingly Effective in Cancer Healthcare

The complexity of cancer can only be better understood and treated with a complex array of tools. In one case, cancer scientists use a single approach—circulating tumor DNA (ctDNA)—in many ways. Plus, even more uses of ctDNA lie ahead.
cancer

MRD: The Future Foundation of Solid Tumor Trials

The terms minimal residual disease, measurable residual disease, and molecular residual disease, interchangeably referred to as MRD, denote what is left after cancer treatment with curative intent. Originally used to monitor patients with hematologic malignancies, MRD is becoming increasingly important in the field of solid tumor oncology because of its correlation with disease outcomes.
digital heads

Relatively Speaking: Unexpected Detours, Can Inconclusive Prenatal Genetic Tests Save Lives?

By Blair Stevens Uncertain genetic testing results are not an unusual event in the field of genetic counseling. Obstetricians routinely refer patients to genetic counselors...

Trending on Inside Precision Medicine

Cancer Cells under microscope

Wyss Institute, Northpond Labs to Develop Cell Therapy Delivery Tech

The research is focused on finding effective methods for getting therapeutic cells to their targets in the body so they can interact with diseased cells.
Researchers from Queen Mary University find that genetic risk scores help predict type 2 diabetes in people of south Asian origin

Polygenic Risk Scores Help Predict Type 2 Diabetes Risk in South Asians

Queen Mary University of London researchers evaluated whether genetic variants linked to type 2 diabetes in Europeans are also relevant in British Pakistani and Bangladeshi people.
Molecule of DNA inside a test tube to signify gene therapy

Belief BioMed’s Hemophilia Gene Therapy Passes Phase I

Belief BioMed’s gene therapy showed very promising results in a Phase I study for hemophilia. This was the first-of-its-kind study in Asia.

Daily News

Trending